Unrelated stem cell transplantation for patients with multiple myeloma

Current Opinion in Hematology

Volumn 17, Issue 6, 2010, Pages 538-543

  Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

allogeneic stem cell transplantation; graft versus myeloma effect; multiple myeloma; reduced intensity conditioning; unrelated donor

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; FLUDARABINE; LENALIDOMIDE; LYMPHOCYTE ANTIBODY; MELPHALAN; THALIDOMIDE; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ALLOIMMUNITY; CANCER PATIENT; CELL FUNCTION; DONOR SELECTION; EUROPE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HLA SYSTEM; HUMAN; LOW DRUG DOSE; MORTALITY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; PATIENT SELECTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; T CELL DEPLETION;

HUMANS; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 78049269003     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833e5b01     Document Type: Review

References (61)

1. Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17:208-215.
2. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allo-geneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000; 18:2273-2281.
3. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88:2787-2793.
4. Hunter HM, Peggs K, Powles R, et al. Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT). Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning: evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005; 128:496-502.
5. Kröger N, Einsele H, Wolff D, Casper J. German study-group multiple myeloma (DSMM). Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German study-group multiple myeloma (DSMM). Bone Marrow Transplant 2003; 31:973-979.
6. Majolino I, Corradini P, Scime R, et al. Allogeneic transplantation of unma-nipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1998; 22:449-455.
7. Gahrton G, Svensson H, Cavo M, et al., European Group for Blood and Marrow Transplantation. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216.
8. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103:4362-4364.
9. Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26:1179-1184.
10. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102:3447-3454.
11. Krö ger N, Schwerdtfeger R, Kiehl M, et al Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002 100 755-760.
12. Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20:1295-1303.
13. Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30:367-373.
14. Krö ger N, Sayer HG, Schwerdtfeger R, et al Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretrans-plantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002 100 3919-3924.
15. Einsele H, Schafer HJ, Hebart H, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121:411-418.
16. Mohty M, Boiron JM, Damaj G, et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34:77-84.
17. Gerull S, Goerner M, Benner A, et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005; 36:963-969.
18. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110-1120.
19. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107:3474-3480.
20. Gahrton G, Bjorkstrand B, Iacobelli S, et al., on behalf of the Chronic Leukemia Working Party. Long-term follow-up of upfront tandem autolo-gous-RIC (reduced-intensity conditioning) allogeneic transplantation versus autologous transplantation (NMAM2000) in multiple myeloma [abstract]. Bone Marrow Transplant 2010; 45 (Suppl 2):O85.
21. Knop S, Liebisch P, Hebart H, et al. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma: an interim analysis of the German DSMM V trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2009; 114:51.
22. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99:1971-1977.
23. Gratwohl A, Baldomero H, Schwendener H, et al. The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant 2010. [Epub ahead of print]. doi: 10.1038/bmt.2010.69.
24. Ballen KK, King R, Carston M, et al. Outcome of unrelated transplants in patients with multiple myeloma. Bone Marrow Transplant 2005; 35:675-681.
25. Shaw BE, Peggs K, Bird JM, et al. Clinical Trials Committee of the British Society of Blood and Marrow Transplantation. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. Br J Haematol 2003; 123:886-895.
26. Kroger N, Shimoni A, Schilling G, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relap sing after autologous transplantation. Br J Haematol 2010; 148:323-331.
27. Georges GE, Maris MB, Maloney DG, et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007; 13:423-432.
28. Bruno B, Sorasio R, Patriarca F, et al. Gruppo Italiano Trapianto Midollo Osseo. Unrelated donor haematopoietic cell transplantation after nonmyeloablative conditioning for patients with high-risk multiple myeloma. Eur J Haematol 2007; 78:330-337.
29. Kroger N, Perez-Simon JA, Myint H, et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10:698-708.
30. Perez-Simon JA, Martino R, Alegre A, et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after nonmyeloablative allogeneic transplantation. Br J Haematol 2003; 121:104-108.
31. Crawley C, Iacobelli S, Bjorkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109:3588-3594.
32. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98:2942-2947.
33. Zander AR, Kroger N, Schleuning M, et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003; 32:355-361.
34. AyukFA, Fang L, Fehse B, et al. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp Hematol 2005; 33:1531-1536.
35. Zand MS, VoT, PellegrinT, et al. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 2006; 107:2895-2903.
36. Ayuk F, Perez-Simon JA, Shimoni A, et al. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica 2008; 93:1343-1350.
37. Kroger N, Shaw B, Iacobelli S, et al. Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtu-zumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005; 129:631-643.
38. RajkumarSV, Blood E, VesoleD, et al., Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-436.
39. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91:1498-1505.
40. Gahrton G, Iacobelli S, Apperley J, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant 2005; 35:609-617.
41. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009; 114:3139-3146.
42. Corradini P,Cavo M, Lokhorst H,et al. Chronic Leukemia Working Partyof the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102:1927-1929.
43. Kolb HJ, Schattenberg A, Goldman JM, et al., European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041-2050.
44. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90:4206-4211.
45. Ayuk F, Shimoni A, Nagler A, et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004; 18:659-662.
46. Alyea E, Weller E, Schlossman R, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001; 98:934-939.
47. Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003; 9:257-265.
48. Kröger N, Kruger W, Renges H, et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001; 112:421-423.
49. Krö ger N, Shimoni A, Zagrivnaja M, et al Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004 104 3361-3363.
50. Sun K,Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci \USA 2004; 101:8120-8125.
51. Krö ger N, Zabelina T, Ayuk F, et al Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006 34 770-775.
52. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107:3575-3583.
53. Minnema MC, van der Veer MS, Aarts T, et al. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4\+Foxp3\+ T cells. Leukemia 2009; 23:605-607.
54. Lioznov M, El-Cheikh J Jr, Hoffmann F, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(\+)) and T (HLA-DR(\+)) cells. Bone Marrow Transplant 2010; 45:349-353.
55. Minnema MC, van der Holt B, Kersten MJ, et al. First interim analysis of HOVON 76: lenalidomide maintenance following non myeloablative allo-geneic stem cell transplantation in patients with multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2009; 114:2885.
56. Krö ger N, Badbaran A, Lioznov M, et al Posttransplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009 37 791-798.
57. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1-or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci \USA 2003; 100:2742-2747.
58. van Bergen CA, Kester MG, Jedema I, et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood 2007; 109:4089-4096.
59. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345:1016-1020.
60. Neelapu SS, Munshi NC, Jagannath S, et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 2005; 36:315-323.
61. Atanackovic D, Arfsten J, Cao Y, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007; 109:1103-1112.